The combination of ifosfamide, etoposide and methotrexate was evaluated in 22 patients with non-Hodgkin's lymphoma (NHL) whose disease had relapsed or was resistant to first-line adriamycin-containing treatment. Only 4 of the 22 patients underwent remissions, 3 of which were complete and 1, partial. Two of the complete remissions occurred in patients with "high-grade" histology who received IMVP-16 after first-line treatment had induced only a partial remission. Bone marrow suppression was the limiting toxicity of this regime, which may be of value in the salvage therapy of selected patients with NHL.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00451654DOI Listing

Publication Analysis

Top Keywords

non-hodgkin's lymphoma
8
treatment refractory
4
refractory relapsed
4
relapsed non-hodgkin's
4
lymphoma ifosfamide
4
ifosfamide methotrexate
4
methotrexate etoposide
4
etoposide combination
4
combination ifosfamide
4
ifosfamide etoposide
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!